Business
Collegium Announces Publication of Real-World Data in Journal of Pain Research
STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index – Multimedia Version (ASI-MV®),” was published in the peer-reviewed medical journal, Journal of Pain Research. “An important part of our commitment to responsible pain management includes ongoing surveillance of real-world data assessing the incidence of abuse, misuse and diversion related to our product portfolio,” said Richard Malamut, M.D., Executive Vice President and Chief Medical Officer of Collegium. “We will continue to support the analysis and publication of real-world data as it becomes available. We believe it is important for the medical and scientific communities to have access to these data to inform treatment decisions when prescribing effective analgesic therapy to treat people suffering from pain.” While the analysis reported in this publication contributes to an understanding of the relative rates of nonmedical use of various opioid products, nothing in the findings should be construed as suggesting that Xtampza ER (oxycodone) extended-release capsules, does not have a high potential for addiction, abuse, or misuse. Please see full Prescribing Information for Xtampza ER including Boxed Warning on addiction, abuse, and misuse and other serious risks. The publication can be found here: link About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at www.collegiumpharma.com. About Xtampza® ER Xtampza ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. INDICATIONS AND USAGEXtampza® ER (oxycodone) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Limitations of Use Because of the risks of a...